Q1 2026 · 13F-HR
Rosalind Advisors, Inc.holdings as filed
Filed 2026-05-14 · accession 0001622627-26-000015
$248.9M
Reported value
38
Positions
2026-03-31
Period end
The Brief · Rosalind Advisors, Inc. · Q1 2026
AI · grounded in 13F
Rosalind Advisors, Inc. exited its position in REPL for a reduction of $13.7M. The fund also closed positions in ATYR and CYTK, reducing exposure by $13.6M and $12.4M respectively. On the buy side, the fund established a new position in PCVX worth $16.9M and added VOR with a $12.5M investment.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 24661P807 | DCTH | DELCATH SYSTEMS, INC. | $30.6M | 12.3% | 3,300,389 | Common | SOLE |
| 98422E103 | XERS | XERIS BIOPHARMA HOLDINGS INC | $18.7M | 7.53% | 3,231,700 | Common | SOLE |
| 31447P100 | FENC | FENNEC PHARMACEUTICALS INC | $17.9M | 7.19% | 2,908,201 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $17.5M | 7.03% | 3,203,721 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $16.9M | 6.77% | 290,000 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $13.4M | 5.37% | 1,036,737 | Common | SOLE |
| 98420X202 | XFOR | X4 PHARMACEUTICALS INC | $13.3M | 5.33% | 3,214,766 | Common | SOLE |
| 929033207 | VOR | VOR BIOPHARMA INC | $12.5M | 5.02% | 700,000 | Common | SOLE |
| M68830112 | MDWD | MEDIWOUND LTD | $12.1M | 4.85% | 749,054 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $11.3M | 4.55% | 2,138,475 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC | $10.5M | 4.21% | 330,000 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $8.8M | 3.53% | 923,057 | Common | SOLE |
| 23256X407 | HELP | CYBIN INC | $7.4M | 2.95% | 1,531,814 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $6.8M | 2.72% | 100,000 | Common | SOLE |
| 45779A846 | NSPR | INSPIREMD INC | $6.4M | 2.56% | 3,905,743 | Common | SOLE |
| 04683R106 | AVIR | ATEA PHARMACEUTICALS INC | $6.3M | 2.53% | 1,171,855 | Common | SOLE |
| 74319B502 | PROF | PROFOUND MEDICAL CORP | $5.4M | 2.16% | 828,118 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $4.9M | 1.97% | 250,401 | Common | SOLE |
| 76029N906 | REPL | REPLIMUNE GROUP INC | $2.7M | 1.10% | 1,275,600 | CALL | SOLE |
| M8001Q126 | PYPD | POLYPID LTD | $2.6M | 1.05% | 597,926 | Common | SOLE |
| 62857J201 | MYO | MYOMO INC | $2.6M | 1.04% | 3,847,272 | Common | SOLE |
| 00444T209 | TLPH | TALPHERA INC | $2.5M | 1.01% | 3,353,916 | Common | SOLE |
| 690469101 | OVID | OVID THERAPEUTICS INC | $2.5M | 0.99% | 1,107,994 | Common | SOLE |
| 24477V105 | DFTX | DEFINIUM THERAPEUTICS INC | $2.4M | 0.95% | 125,000 | Common | SOLE |
| 68277Q105 | OKUR | ONKURE THERAPEUTICS INC | $1.8M | 0.74% | 443,763 | Common | SOLE |
| 53630X203 | LPCN | LIPOCINE INC | $1.8M | 0.71% | 221,616 | Common | SOLE |
| 64134X201 | NRXS | NEURAXIS INC | $1.7M | 0.68% | 286,138 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $1.1M | 0.45% | 75,000 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $1.1M | 0.45% | 200,000 | Common | SOLE |
| 46090E953 | QQQ | INVESCO QQQ TR | $1.1M | 0.42% | 250,000 | PUT | SOLE |
| 03843E104 | AQST | AQUESTIVE THERAPEUTICS INC | $1.0M | 0.42% | 250,000 | Common | SOLE |
| 78462F953 | SPY | SPDR S&P 500 ETF TR | $958,500 | 0.39% | 125,000 | PUT | SOLE |
| 09077D209 | BFRI | BIOFRONTERA INC | $941,645 | 0.38% | 1,163,962 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $813,000 | 0.33% | 100,000 | Common | SOLE |
| M8211G108 | RGNT | REGENTIS BIOMATERIALS LTD | $768,363 | 0.31% | 251,510 | Common | SOLE |
| 92790C954 | VRDN | VIRIDIAN THERAPEUTICS INC | $52,720 | 0.02% | 263,600 | PUT | SOLE |
| N90064901 | QURE | UNIQURE NV | $0 | — | 295,800 | CALL | SOLE |
| 04272N902 | AVBP | ARRIVENT BIOPHARMA INC | $0 | — | 108,900 | CALL | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.